Drug Profile
Tetracosactide depot - Slan Medicinal Holdings
Alternative Names: Cosyntropin depot - Slan Medicinal Holdings; Long acting cosyntropin - Slan Medicinal Holdings; Synthetic ACTH Depot - Slan Medicinal HoldingsLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Mallinckrodt Inc.
- Developer Assertio Therapeutics; Slan Medicinal Holdings
- Class Anti-inflammatories; Antidepressants; Corticosteroids; Diagnostic agents; Immunotherapies; Melanocortins; Peptides
- Mechanism of Action Melanocortin receptor agonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Adrenal insufficiency
- No development reported Infantile spasms
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for clinical-Phase-Unknown development in Infantile spasms in USA (Parenteral)
- 24 Oct 2019 Update: KDM, HE
- 21 Oct 2019 West Therapeutic Development (Slan Medicinal Holdings) receives complete response letter from the FDA for tetracosactide depot in Adrenal insufficiency (Diagnosis)